Skip to NavigationSkip to content

Empagliflozin (Jardiance®) receives SMC approval for treatment of heart failure

Published on 13/10/21 at 10:36am

The Scottish Medicines Consortium (SMC) has announced that empagliflozin (Jardiance®) has been accepted for use by NHS Scotland, for the treatment of patients with symptomatic heart failure with reduced ejection fraction. This recommendation ensures that people in Scotland living with this condition will now have access to empagliflozin via the NHS.

Heart failure is one of the leading causes of hospitalisations in the UK, with over 47,500 people in Scotland living with this condition, and the incidence is increasing. Scotland has a high prevalence of risk factors, and the proportion of people in Scotland with heart failure for all ages is 1.44% in men and 0.82% in women. This rises to 8.72% and 5.97% for men and women over the age of 75.

Heart failure is a chronic, long-term condition, occurring when the heart is unable to pump blood around the body properly. This can cause shortness of breath and fatigue in patients, potentially severely impacting their quality of life. This highlights the ever-increasing importance of new treatment options for people suffering from heart failure.

“46 people are diagnosed with heart failure every day in Scotland,” said Mark Petrie, Professor of Cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

“Heart failure is a progressive disease that can prove fatal if left untreated and lead to an increased risk of hospitalisation. By accepting empagliflozin, the SMC has provided people living with heart failure in Scotland with an important new treatment option.”

“Today’s positive recommendation by the SMC means that empagliflozin will be available through NHS Scotland to people in Scotland living with heart failure with reduced ejection fraction,” said Dr Douglas Clark, Head of Medical Affairs at Boehringer Ingelheim UK & Ireland. “Boehringer Ingelheim looks forward to collaborating with health boards across Scotland to ensure optimal access to people whose lives have been impacted by this chronic, progressive and life-limiting disease.”

Lina Adams


Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches